Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis

BACKGROUND: Recently, the addition of inhaled corticosteroid (ICS) to long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been recommended for patients with COPD who have severe symptoms and a history of exacerbations because it reduces the exacerbati...

Descripción completa

Detalles Bibliográficos
Autores principales: Koarai, Akira, Yamada, Mitsuhiro, Ichikawa, Tomohiro, Fujino, Naoya, Kawayama, Tomotaka, Sugiura, Hisatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218448/
https://www.ncbi.nlm.nih.gov/pubmed/34154582
http://dx.doi.org/10.1186/s12931-021-01777-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218448/
https://www.ncbi.nlm.nih.gov/pubmed/34154582
http://dx.doi.org/10.1186/s12931-021-01777-x

Ejemplares similares